Dark

Check out our Dark Pool Levels

CMLTU
CM Life Sciences III Inc. Unit
stock NASDAQ

Inactive

Dec 17, 2021

8.87USD-6.533%(-0.62)11,702

Pre-market

0.00USD-100.000%(-9.49)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 17, 2021

12:45PM EST -- Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceeds -- Combined company to trade on Nasdaq Global Market under ticker EQRX GlobeNewswire Inc

Dec 2, 2021

07:00AM EST EQRx and CM Life Sciences III Announce Effectiveness of Form S-4 Registration Statement and Stockholder Meeting Details to Vote on Proposed Business Combination Business Wire

Nov 29, 2021

08:00AM EST EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference Business Wire

Nov 22, 2021

07:00AM EST EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa Business Wire

Nov 18, 2021

07:00AM EST EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership Business Wire

Nov 16, 2021

08:00AM EST EQRx Launches "Remaking Medicine: On The Record" Investor Video Series Business Wire

Oct 19, 2021

03:33PM EDT EQRx and NHSE Sign Memorandum of Understanding to Enter into England's First Population Health Partnership for Cancer Drugs Business Wire

Oct 6, 2021

06:00AM EDT EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs Business Wire

Sep 27, 2021

08:00AM EDT EQRx Appoints Kathy Giusti to Board of Directors Business Wire

Sep 17, 2021

07:08AM EDT EQRx Presents Phase 3 Data Demonstrating Progression-Free Survival Benefit With Sugemalimab Consolidation Therapy RTTNews

07:00AM EDT EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021 Business Wire

Sep 13, 2021

08:40PM EDT EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC Business Wire

Sep 7, 2021

08:00AM EDT EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference Business Wire

Aug 18, 2021

07:00AM EDT EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer Business Wire

Aug 6, 2021

03:37PM EDT Corvex, Casdin Backed SPAC To Merge With EQRx In $1.8B Deal Benzinga

07:10AM EDT CM Life Sciences II Shares Were Halted Ahead Of News: EQRx Reports SPAC Deal With CM Life Sciences II For $1.8B In Cash Proceeds Benzinga

07:10AM EDT CM Life Sciences II Shares To Resume Trade At 7:30 a.m. EDT Benzinga

07:09AM EDT EQRx Reports SPAC Deal With CM Life Sciences II For $1.8B In Cash Proceeds Benzinga

07:00AM EDT EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III Business Wire

May 26, 2021

04:19PM EDT CM Life Sciences III Inc. Announces Separate Trading of Its Shares of Class A Common Stock and Warrants, on or About May 28, 2021 Benzinga

Apr 9, 2021

04:20PM EDT CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering Business Wire

Apr 7, 2021

10:26AM EDT CM Life Sciences III Shares Open For Trade At $10.60; IPO Priced At $10/Unit Benzinga

09:10AM EDT CM Life Sciences III Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $10/Unit Benzinga

12:13AM EDT CM Life Sciences III Prices IPO Of 48 Mln Units At $10/unit RTTNews

Apr 6, 2021

10:10PM EDT CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $480 Million Initial Public Offering Business Wire

Share